Drug Trial Radar · NCT07949344
A Post-Marketing Trial to Evaluate the Safety and Efficacy of Quizartinib in Chinese Participants With Newly Diagnosed FMS-like Tyrosine Kinase 3-internal Tandem Duplication [FLT3-ITD] (+) Acute Myeloid Leukemia (AML)
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Jun 30, 2030
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The clinical trial is designed to assess the safety of quizartinib in newly diagnosed FLT3-ITD (+) AML in Chinese participants.
Conditions
- Acute Myeloid Leukemia
Interventions
QuizartinibDrug
Participants will receive quizartinib 40 mg orally once daily for 14 days during the induction and consolidation phases and 30 mg orally once daily, increased to 60 mg once daily in the maintenance phase.
ChemotherapyDrug
Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Genetic
Allogeneic HSCT is one of the options for consolidation therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Grade Greater than or Equal to (≥)3 Treatment-Related Adverse Events (TRAEs)Time frame: Up to approximately 39 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.